Clinical trial · Interventional
Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies
A Randomized, Serum Level-targeted Study Investigating the Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Patients With Various Refractory Malignancies
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will test the safety, tolerance, and efficacy of different doses of oral gallium maltolate. Patients will receive oral gallium maltolate twice daily for 28-consecutive days followed by 14 days off treatment. This dosing cycle will be repeated. Adverse effects will be assessed and the levels of gallium in serum will be measured. Any effect of the drug on the cancer and any improvement in cancer-related symptoms will also be measured.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Neoplasms | Bladder Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
| Prostatic Neoplasms | Prostate Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Gallium maltolate | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with hormone refractory prostate cancer, refractory multiple myeloma, refractory bladder cancer, or malignant lymphoma; * life expectancy of ≥6 months, * Zubrod Performance Status of ≤2, * adequate bone marrow function, renal function, liver function and pulmonary function; * age ≥ 18 years; * willing and able to give informed consent; and * effective contraceptive use or non child-bearing potential. Exclusion Criteria: * 10% weight loss in the previous 3 months; * active serious infection not controlled by antibiotics; * initiation of bisphosphonates treatment within 30 days; * participation in other research study within 30 days; * uncontrolled brain metastasis, * prior intrathecal chemotherapy or whole-brain radiotherapy, * inability to comply with protocol or undergo specified tests; * other active malignancy; * optic neuritis, and * routine use of diuretics (for initial phase of study only).
References
Publications (0)
Data not yet available